Conclusion
In this study, the molecular mechanisms and related pathways that may cause clinical severity among mild and severe CF siblings with same genotype were identified. The data obtained as a result of this study will provide opportunity for identification and development of new target molecules for treatment in the future. Also determination of candidate genes will pave the way for their use for both prognostic and therapeutic biomarkers especially for preventing the progression of hepatic involvement. Determination of differentially expressed genes and associated pathways between CF patients and controls may provide new insights into molecular pathology of not only CF but also other respiratory diseases.